Plenary Session
387 episodes - English - Latest episode: 4 days ago - ★★★★★ - 722 ratingsA podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail [email protected]
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
2.18 Questions of the Week, Talking About Toxicity, ASCO Guidelines Authors' COI with Dr. Eitan Amir
October 18, 2019 22:49 - 1 hour - 72.8 MBThis week we begin with a critique of the recent perspective article in the New England Journal of Medicine, titled "Talking about Toxicity — 'What We’ve Got Here Is a Failure to Communicate'". After that we interview Dr. Eitan Amir on his paper on undisclosed conflicts of interest among authors of ASCO guidelines. Interspersed between segments of the interview, we invite guest Dr. Sven Olson on to offer a correction to a recent Hem/Onc boards question of the week on Lynch Syndrome (original ...
2.17 Questions of the Week, BEACON, & Use of Subacuate Rehab with Dr. Jonathan Yeh
October 08, 2019 19:23 - 1 hour - 82 MBWe start this week's episode with a quick breakdown of why the recent BEACON trial is "the worst trial" host VP has ever read. After that, we have two questions of the week: one from medical student Audrey Tran, and one inspired by the Hem/Onc boards from Dr. Sven Olson. We end with an interview with Dr. Jonathan Yeh of Johns Hopkins University School of Medicine on his recent paper: "Has There Been a Shift in Use of Subacute Rehabilitation Instead of Hospice Referral Since Immunotherapy Has ...
2.16 FLAURA & What Truly Matters in the Career of an Academic Physician with Dr. Vinay Prasad
October 02, 2019 22:27 - 1 hour - 93.5 MBThis week we break down the limitations of the recent FLAURA trial and then we're back in the Plenary Session Mobile Command Unit! We have a special guest host, Dr. Christopher Booth of Queen's University in Kingston, Ontario, Canada. He and Dr. Bishal Gyawali, also of Queen's University, conduct a reverse interview with our usual host, Dr. Vinay Prasad of Oregon Health & Science University, on his career, the formation of Plenary Session, and what truly matters in the career of an academic p...
2.15 Bonus! The Value of Progression-Free Survival as a Treatment Endpoint with Dr. Michael Raphael
September 26, 2019 15:04 - 35 minutes - 33.7 MBThis BONUS episode is an interview with Dr. Michael Raphael of Sunnybrook Health Sciences Centre in Toronto, Ontario on his new paper out today in JAMA Oncology: "The value of progression-free survival as a treatment endpoint among patients with advanced cancer: a systematic review and qualitative assessment of the literature". Value of PFS: https://jamanetwork.com/journals/jamaoncology/article-abstract/2751879 Back us on Patreon! www.patreon.com/plenarysession
2.14 Questions of the Week & Qualifications of a Fellowship Applicant with Dr. Jeremy Cetnar
September 24, 2019 22:24 - 1 hour - 99.3 MBThis week we sit down with Dr. Jeremy Cetnar, director of the Oregon Health & Science University Hematology & Oncology Fellowship Program. In this far-ranging interview, we discuss what he is looking for when reviewing applications to the fellowship program. We also have two questions of the week: one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology. Tweetorials: http://doi.org/10.1056/NEJMp1906790 Back us on Patreon! www.patreon.com/plena...
2.13 BONUS! RCTs Supporting Approvals of Cancer Drugs by EMA with Dr. Huseyin Naci
September 20, 2019 22:50 - 39 minutes - 40.2 MBOn this week's BONUS episode, we sit down with Dr. Huseyin Naci, Assistant Professor of Health Policy at the London School of Economics, to discuss his new paper that came out Wednesday (producer's edit: not "yesterday" as said in the podcast - apologies for the delay!) in the British Medical Journal. The paper's titled "Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectiona...
2.12 Questions of the Week, Ethics of RCTs, & Transmission and Medical Overuse with Dr. Dan Morgan
September 17, 2019 18:01 - 1 hour - 99.6 MBWe begin this week's episode by revisiting last week's topic on the ethics of randomized controlled trials (RCTs) to address some of the controversy stirred up by our episode. We transition from there to an interview with Dr. Dan Morgan of the University of Maryland School of Medicine on hospital transmission and medical overuse. We have two questions of the week, as well -- one from Ian Straehley, inspired by the USMLE Step 2 CK; and one from Audrey Tran, inspired by the life of a medical st...
2.11 Questions of the Week, When RCTs are Necessary, & AYA Oncology with Dr. Adam Duvall
September 12, 2019 16:44 - 1 hour - 100 MBAfter a hiatus from our segment on reviewing recent trials, we return to discuss the need for randomized controlled trials (RCTs). In the wake of the 2019 World Conference on Lung Cancer, we focus on whether a phase III trial of selpercatinib (LOXO-292) in RET rearranged lung cancer is feasible, practical, and ethical. We also have two questions of the week in this episode -- one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology -- as well as ...
2.10 Questions of the Week: the USMLE Step 2 CK, the MKSAP, & Hematology/Oncology
September 05, 2019 19:33 - 23 minutes - 23.3 MBWe have three questions for you this week: one from Ian Straehley, inspired by the USMLE Step 2 CK; one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology. Back us on Patreon! www.patreon.com/plenarysession
2.09 Questions of the Week & Informed Consent in Clinical Trials with Dr. Lynn Jansen
August 28, 2019 17:13 - 1 hour - 76.8 MBWe start this week with two Questions of the Week: the first is from Ian Straehley on the USMLE Step 2 CK, and the second is from Dr. Sven Olson on hematology/oncology. We end with an interview with Dr. Lynn Jansen of OHSU on the therapeutic misconception, optimism bias, and a deep discussion of the ethics of consenting patients for enrollment in early-phase clinical research trials. Back us on Patreon! www.patreon.com/plenarysession
2.08 Questions of the Week: the MKSAP, the USMLE Step 2 CK, & From a Med Student
August 22, 2019 21:42 - 37 minutes - 37.5 MBWe have three questions for you this week: one from Dr. Derrick Tao, inspired by the MKSAP; one from Ian Straehley, inspired by the USMLE Step 2 CK; and one from Audrey Tran, inspired by her journey through medical school. Back us on Patreon! www.patreon.com/plenarysession
2.07 Translational Research & Physical Examination Pet Peeves with Dr. Adam Cifu
August 16, 2019 17:16 - 1 hour - 74.7 MBWe start this week's episode with a Question of the Week from medical student Audrey Tran on translational research and medical student training. Afterwards, we have an in-depth interview with Dr. Adam Cifu of the University of Chicago on his recent publication: "Physical Examination Pet Peeves". Pet Peeves: doi.org/10.4300/JGME-D-18-01063.1 Back us on Patreon! www.patreon.com/plenarysession
2.06 Heart Failure, Choosing a Specialty, & the Bayesian Approach with Dr. Frank Harrell
August 06, 2019 23:31 - 1 hour - 91 MBWe're back with more questions of the week! Our first question, from Ian Straehley, is inspired by the USMLE Step 2 CK; our second question, from Audrey Tran, is on deciding on a medical specialty. We end the episode with an interview with Dr. Frank Harrell of Vanderbilt University on the Bayesian approach to statistical thinking. Back us on Patreon! www.patreon.com/plenarysession
2.05 Reup! Cancer Screening 101 with Dr. Adam Obley
July 31, 2019 15:26 - 1 hour - 71.8 MBIn this REUP episode, we replay a section of our interview with Dr. Adam Obley of OHSU: a primer on cancer screening. This audio was first aired on episode 2.03. Not So Silver Lining: doi.org/10.1001/archinternmed.2011.73 Mammography Screening: Truth, Lies and Controversy: www.crcpress.com/Mammography-Screening-Truth-Lies-and-Controversy/Gotzsche/p/book/9781846195853 Back us on Patreon! www.patreon.com/plenarysession
2.04 Reup! Tumor-Treating Fields for Glioblastoma with Dr. Michael Hayes
July 30, 2019 19:33 - 35 minutes - 36.4 MBIn this REUP episode, we replay a section of our interview with Dr. Michael Hayes of Kaiser Permanente. This audio was first aired on episode 2.01. The interview is on the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme. TTF: doi.org/10.1016/j.jcpo.2019.100189 Back us on Patreon! www.patreon.com/plenarysession
2.03 Dr. Charles Moertel and the Modern Oncologist & Cancer Screening 101 with Dr. Adam Obley
July 23, 2019 22:37 - 2 hours - 123 MBThis week we launch a new segment on Plenary Session: Question of the Week! We invite Dr. Sven Olson on to ask a sample hematology/oncology boards question and we invite Audrey Tran on to ask a question from a medical student. Before that, we talk about the legacy of Dr. Charles Moertel and how modern oncologists, in contrast, will be remembered. We end the episode with an interview with Dr. Adam Obley of OHSU -- his fourth appearance on the podcast! -- on cancer screening. Dr. Moertel's obi...
2.02 BONUS! Improving Access to Prescription Drugs through Policy Change with Dr. Stacie Dusetzina
July 17, 2019 19:13 - 44 minutes - 41.4 MBThis BONUS episode is a recording of a lecture that Dr. Stacie Dusetzina of Vanderbilt University gave for grand rounds at OHSU on June 19, 2019. The lecture is on the cost of prescription drugs and out-of-pocket spending. Back us on Patreon! www.patreon.com/plenarysession
2.01 Selinexor, ECHELON-2, Parachutes, Tumor-Treating Fields, & MedTwitter
July 12, 2019 21:50 - 2 hours - 154 MBWelcome to season 2! We're starting this season off with a little bit of everything: a critique of the FDA's accelerated approval of selinexor for penta-refractory multiple myeloma; an interview with Dr. John Reneau of Ohio State University on ECHELON-2 (brentuximab vedotin in t-cell lymphomas); an interview with Dr. Michael Hayes of Kaiser Permanente on parachutes in medicine plus the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma mul...
1.68 Voxeletor with Dr. Olson & Humanizing Cancer, Defining Cancer, and more with Dr. David Steensma
July 05, 2019 18:01 - 2 hours - 118 MBWe begin this week's episode by breaking down the recent phase III trial on voxeletor in sickle cell disease with Dr. Sven Olson of OHSU. Next, we feature guest Dr. David Steensma of the Dana-Farber Cancer Institute in a far-reaching interview on being well-read, running a small lab, humanizing cancer, learning from our past use of erythropoiesis-stimulating agents, understanding the headache of contract research organizations, defining cancer, and more! Voxeletor in Sickle Cell: doi.org/10....
1.67 MONALEESA-7 and the Cost of Cancer Drugs with Dr. Stacie Dusetzina
June 27, 2019 22:53 - 2 hours - 135 MBThis week we begin the episode by discussing MONALEESA-7 and why ribociclib has been shown to increase overall survival while palbociclib has not. We finish the episode with an in-depth interview with Dr. Stacie Dusetzina of Vanderbilt University on her work in pharmacoeconomics, specifically we discuss her work on the market value of cancer drugs. MONALEESA-7: doi.org/10.1056/NEJMoa1903765 Free drug samples are a marketing tool: doi.org/10.2105/AJPH.2007.114249 Back us on Patreon! www.pa...
1.66 Employing Medical Writers & Frequentist vs Bayesian Methods with Dr. Allen Pannell
June 20, 2019 19:19 - 1 hour - 66.6 MBThis week we open with a critical take on our current system of disseminating scientific research, specifically focusing on the prevalence of -- and dependence on -- medical writers. In the second half of the episode, we interview Dr. Allen Pannell of the Haslam College of Business at the University of Tennessee on using a Frequentist approach vs a Bayesian approach in the context of a single clinical trial. Frequentist vs Bayesian: doi.org/10.1136/bmjopen-2018-024256 Dr. Pannell's breast c...
1.65 BONUS! Focusing and Building Your Presence on Twitter
June 12, 2019 23:24 - 39 minutes - 41.4 MBIn this BONUS episode we give advice on how to use Twitter effectively: how to focus your content, how to build your Twitter following, and how to conceptualize of the platform as an information network. Back us on Patreon! www.patreon.com/plenarysession
1.64 Effectiveness of Cancer Screening with Dr. Joaquín Chapa and POLO with Dr. Emerson Chen
June 06, 2019 18:31 - 1 hour - 70.2 MBThis week we discuss the recent paper "Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?" with its author, Dr. Joaquín Chapa of OHSU. We then revisit the POLO trial with Dr. Emerson Chen of OHSU, who disagrees with last episode's analysis. Effectiveness of Screening: doi.org/10.1016/j.mayocp.2019.02.016 POLO: doi.org/10.1056/NEJMoa1903387 Back us on Patreon! www.patreon.com/plenarysession
1.63 POLO, TITAN, & from ASCO: FDA Approval, Surrogate Endpoints, and Patient Experience
June 04, 2019 17:27 - 1 hour - 90.2 MBThis week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", which was given in a shortened version at ASCO. POLO: doi.org/10.1056/NEJMoa1903387 TITAN: doi.org/...
1.62 Rates of Cancer Screening, BILCAP Outcry, Waterfall Plots and Response Rate, & Dr. Jeff Sharman
May 23, 2019 20:47 - 1 hour - 101 MBWe begin this episode by responding to listener feedback from episode 1.61's discussion of clinic appointment time and rates of cancer screening. We also tackle listeners' outcry over our take-down of BILCAP (spoiler alert: BILCAP is still a null trial) and how outcry like this highlights the need to train clinicians to think probabilistically. From there, we move on to discussing the recent paper by Myung Sun Kim in JAMA Network Open on waterfall plots and how they are a visual distortion of...
1.61 Postpublication Metrics of RCTs, PCP Appointment Time, Bortezomib, & Dr. Christopher Booth
May 15, 2019 23:13 - 2 hours - 155 MBThis week we cover three papers -- "Postpublication Metrics of Randomized Clinical Trials With and Without Null Findings" by Murray et al. in JAMA, "Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening" by Hsiang et al. in JAMA Network Open, and "Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers" by Drilon et al. in M...
1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung
May 09, 2019 23:05 - 1 hour - 89.7 MBWe revisit I-PREDICT, discuss the "Imputability of Adverse Events to Anticancer Drugs" (a letter published recently in the New England Journal of Medicine), and interview Dr. Daniel Hartung of Oregon State University's College of Pharmacy on his vast knowledge of the cost of drugs, specifically addressing Acthar gel and multiple sclerosis drugs. Imputability of Adverse Events: doi.org/10.1056/NEJMc1900053 Back us on Patreon! www.patreon.com/plenarysession
1.59 BONUS! Should Evidence Come with an Expiration Date? with Palmer Greene
May 08, 2019 22:07 - 18 minutes - 21 MBIn this BONUS episode, we interview Palmer Greene, a fourth-year medical student at the University of Chicago Pritzker School of Medicine, on his recent paper: "Should Evidence Come with an Expiration Date?", published in the Journal of General Internal Medicine. Expiration Date?: doi.org/10.1007/s11606-019-05032-4 Back us on Patreon! www.patreon.com/plenarysession
1.58 Magic Mouthwash with Dr. Arjun Gupta & Precision Oncology with Dr. Talal Hilal
May 07, 2019 16:12 - 1 hour - 85.4 MBThis week we discuss three paired papers on precision oncology published in Nature Medicine and then, later in the episode, go in-depth on the implications of these negative studies with Dr. Talal Hilal of the Mayo Clinic. We also discuss the use of magic mouthwash for oral mucositis with Plenary Session fan, Dr. Arjun Gupta of Johns Hopkins University. WINTHER: doi.org/10.1038/s41591-019-0424-4 TARGET: doi.org/10.1038/s41591-019-0380-z I-PREDICT: doi.org/10.1038/s41591-019-0407-5 Magic mou...
1.57 BONUS! Control Arm Quality in RCTs Leading to Anticancer Drug FDA Approval with Dr. Talal Hilal
May 02, 2019 16:58 - 33 minutes - 32.5 MBIn this BONUS episode, we interview Dr. Talal Hilal of the Mayo Clinic on his paper that was published today in JAMA Oncology, titled "Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration". Control Arm Quality: doi.org/10.1001/jamaoncol.2019.0167 Back us on Patreon! www.patreon.com/plenarysession
1.56 BONUS! Real World Data & the Search for Meaningful Cancer Care with Dr. Christopher Booth
May 01, 2019 23:01 - 48 minutes - 50.8 MBThis BONUS episode is the recording of a Grand Rounds lecture that Dr. Christopher Booth of Queen's University in Kingston, Canada gave this morning (May 1, 2019) at OHSU. The title is "Achieving the Achievable: Real World Data and the Search for Meaningful Cancer Care". Back us on Patreon! www.patreon.com/plenarysession
1.55 Role of a Professional Society & More with Dr. Cliff Hudis of ASCO
April 29, 2019 22:20 - 1 hour - 99.7 MBThis week we sit down with Dr. Cliff Hudis, the CEO of the American Society of Clinical Oncology, to discuss the role of a professional society, the evolution of oncology, building a career, and more. Back us on Patreon! www.patreon.com/plenarysession
1.54 Association of Patient Characteristics and Tumor Genomics with Clinical Outcomes & SABR-COMET
April 18, 2019 17:00 - 33 minutes - 33.9 MBIn this week's episode, we break down two recently published papers. The first is "Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database" by Singal et al., published in JAMA. The second is "Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial" by Palma et al., publishe...
1.53 CALGB 50303, REMoDL-B, & REMS, Orphan Drug Act, and Role of the FDA with Dr. Ameet Sarpatwari
April 11, 2019 17:05 - 1 hour - 82.3 MBWe begin this episode with a discussion of two recent clinical trials in lymphoma: CALGB 50303 and REMoDL-B, respectively published in the Journal of Clinical Oncology and The Lancet Oncology. We include a primer on the history of lymphoma and the development of R-CHOP. We follow that with an in-depth interview with Dr. Ameet Sarpatwari of the Harvard Medical School on Risk Evaluation and Mitigation Strategies (REMS), the Orphan Drug Act, and, broadly, the purpose of the US FDA. CALGB 50303...
1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson
April 04, 2019 16:25 - 59 minutes - 60.5 MBIn this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Can...
1.51 BONUS! Study Time Reduction Using Surrogate End Points with Dr. Emerson Chen
April 02, 2019 19:27 - 25 minutes - 27.3 MBIn this BONUS episode, we sit down for a quick interview with Dr. Emerson Chen of OHSU on his recent paper in JAMA Internal Medicine on how using surrogate end points as opposed to overall survival for FDA approval for oncology drugs only results in a reduced drug development time of approximately 11 months. Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351 Back us on Patreon! www.patreon.com/plenarysession
1.50 Replacing RCTs, Physicians on Twitter, Open-Access, & Orthopedics with Dr. Kathryn Schabel
March 29, 2019 19:04 - 1 hour - 117 MBThis week we tackle the recent paper published in the Journal of Clinical Oncology titled "Comparison of Population-Based Observational Studies With Randomized Trials in Oncology" as well as a couple papers lamenting physicians' use of Twitter and the open-access model for journal publishing. We end the episode with an in-depth interview with Dr. Kathryn Schabel of OHSU on orthopedic surgery and how she practices. Observational Studies vs RCTs: doi.org/10.1200/JCO.18.01074 Back us on Patre...
1.49 Student Questions, Boeing 737 Max, Pancreatic Surveillance, Leukemia Drugs with Dr. Elihu Estey
March 22, 2019 18:25 - 1 hour - 111 MBWe begin this episode by answering questions from a med student who is a Plenary Session fan. We transition from there to a discussion of the recent news stories on the FAA's handling of the Boeing 737 Max controversy and how this reflects on other USA regulatory agencies like the FDA. After a critique of the recent paper "Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance" published in the Journal of Clin...
1.48 Falsified Data in Meta-Analyses and the Expert Halo Effect with Dr. Stephanie Halvorson
March 13, 2019 23:04 - 1 hour - 58.7 MBThis week we dive deep into an article in JAMA IM on falsified data in meta-analyses. We also discuss the recent JAMA viewpoint "Reducing the Expert Halo Effect on Pharmacy and Therapeutics Committees" with its author, Dr. Stephanie Halvorson of OHSU. Falsified data: doi.org/10.1001/jamainternmed.2014.7774 Expert Halo Effect: doi.org/10.1001/jama.2018.20789 Back us on Patreon! www.patreon.com/plenarysession
1.47 BONUS! Medical Reversal: Class Lecture
March 11, 2019 23:06 - 56 minutes - 57.3 MBThis BONUS episode is a lecture on medical reversal that was pre-recorded for a class at Harvard Medical School. The recording was played for students in February of 2019 and followed by a Q&A. The slides referenced are available to Patreon supporters. Back us on Patreon! www.patreon.com/plenarysession
1.46 BONUS! Personal Finances with Dr. Tom Beer
March 08, 2019 17:10 - 1 hour - 72.9 MBIn this bonus episode, we bring back Dr. Tom Beer of OHSU from episode 1.33 to discuss how to manage your personal finances. The interview is aimed at young physicians, but there is something for all audiences as we cover a broad range of topics: paying off loans, optimizing retirement savings, buying a home, and investing. Back us on Patreon! www.patreon.com/plenarysession
1.45 Real-World Data, Gottlieb, & Using the EHR for Meaningful Improvement with Dr. Deborah Cohen
March 06, 2019 22:10 - 59 minutes - 58.6 MBThis week's episode begins with praise for the recent article by Booth CM, Karim S, and Mackillop WJ on real-world data published in Nature Reviews Clinical Oncology. Next, we tackle the resignation of Scott Gottlieb as FDA commissioner and how we can measure the success of the FDA. Finally, we have an interview with Dr. Deborah Cohen of OHSU on effective communication between the clinician and the patient and how we can use data from the Electronic Health Record to make meaningful improvemen...
1.44 BONUS! Screen Time and Children's Performance
March 01, 2019 23:25 - 46 minutes - 39.1 MBThis BONUS episode is the recording of a lecture given as part of the medical school class Appraising Medical Literature, taught at OHSU. This clip from the class critiques the recent JAMA Pediatrics paper "Association Between Screen Time and Children’s Performance on a Developmental Screening Test". Screen Time: doi.org/10.1001/jamapediatrics.2018.5056 Back us on Patreon! www.patreon.com/plenarysession
1.43 Andexanet Alfa with Dr. Tom Deloughery & National Medicaid Policy with Dr. John McConnell
February 22, 2019 23:17 - 1 hour - 88 MBIn this episode we discuss the controversy over the recent article in NEJM, "Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors", with Dr. Tom Deloughery of OHSU. We end with an interview with Dr. John McConnell, also of OHSU, on health economics and Medicaid. Andexanet Alfa: doi.org/10.1056/NEJMoa1814051 Back us on Patreon! www.patreon.com/plenarysession
1.42 Caplacizumab for TTP with Dr. Sven Olson & Economics of Drug Pricing with Dr. Inma Hernández
February 13, 2019 18:47 - 1 hour - 75.3 MBIn the first half of this episode, Dr. Sven Olson of OHSU joins us to help critique the recent NEJM paper, "Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura". In the second half, we interview Dr. Inmaculada Hernández of the University of Pittsburgh on her work on the economic principles behind runaway drug prices. Caplacizumab: doi.org/10.1056/NEJMoa1806311 Back us on Patreon! www.patreon.com/plenarysession
1.41 Geneva Oath and Financial Relationships Among Guideline Authors with Dr. Joshua Niforatos
February 09, 2019 00:35 - 57 minutes - 56.9 MBWe feature two interviews this week: the first is a hallway conversation with [soon-to-be] Dr. Antonious Hazim of OHSU on the Declaration of Geneva and the second is a discussion with [soon-to-be] Dr. Joshua Niforatos on his recent paper in The American Journal of Emergency Medicine, titled "Financial relationships with industry among guideline authors for the management of acute ischemic stroke". Financial relationships: doi.org/10.1016/j.ajem.2019.01.037 Back us on Patreon! www.patreon.co...
1.40 The World of Hematology with Dr. Thomas Deloughery
February 06, 2019 00:46 - 1 hour - 64.3 MBThis episode features an interview with hematologist Dr. Thomas Deloughery of OHSU. We cover a broad range of topics including 23andMe, wilderness medicine, academia, and Twitter. We'll be back next week with our regular introductory monologue! Back us on Patreon! www.patreon.com/plenarysession
1.39 Looking Back On a Tenure in Medicine with Dr. Alex Denes
February 02, 2019 00:34 - 1 hour - 53.3 MBIn this episode we interview Dr. Alex Denes of OHSU on his decades-long career in medicine: what practices have changed and what have stayed the same. No monologue this week - we'll be back next week with more insights! Back us on Patreon! www.patreon.com/plenarysession
1.38 Lartruvo, New Directions for Cancer Trials, Gene Expression Profiling, & Dr. Miriam Knoll
January 26, 2019 00:47 - 1 hour - 92 MBIn this episode we tackle Eli Lilly's drug Lartruvo (olaratumab) and the under-powered phase II trial that led to its FDA accelerated approval; a viewpoint in JAMA on new directions for cancer trials; and gene expression profiling for carcinoma of unknown primary. We end with an interview with Dr. Miriam Knoll of Hackensack Meridian Health on employment after residency or fellowship, residency training, and the medical specialty pipeline. Back us on Patreon! www.patreon.com/plenarysession
1.37 BONUS! Medical Reversal for a General Audience
January 18, 2019 16:34 - 43 minutes - 35.7 MBThis BONUS episode is the recording of a talk given at the Salem City Club on January 11, 2019. It's the talk on medical reversal that has been featured in previous episodes, but this time the format and content have been updated for a broader, more general audience. Back us on Patreon! www.patreon.com/plenarysession